A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder

Abstract

A randomised placebo-controlled “dose relation study” was conducted in 549 patients who met the criteria for major depressive disorder, to evaluate the efficacy and safety of three doses regimens of agomelatine during 6 weeks: low fixed dosage (10mg/day, n=133), fixed dosage (25mg/day, n=138) and a flexible dosage with up-titration in case of insufficient improvement at week 2 (25–50mg/day, n=137). At last post-baseline assessment, there were significant and incremental placebo-agomelatine differences on mean HAM-D17 total scores in favour of each agomelatine dose regimen (2.46±0.76 points, p=0.001 at 10mg; 4.71+0.75 points, p<0.0001 at 25mg and 4.92±0.76 points, p<0.0001 at 25–50mg) with statistically significant differences between 25mg and 25–50mg dose regimens compared to the 10mg dose. The response rate according to HAM-D17 was significantly higher in patients taking agomelatine than those taking placebo (difference of 16.1% at 10mg p=0.005; 25.9% and 27.4% respectively at 25mg and 25–50mg, p<0.0001). The benefit of agomelatine was demonstrated in the subgroup of severely depressed patients in the 25mg and 25–50mg/day regimens. Consistent clinical response according to CGI variables and better social functioning were found in patients receiving agomelatine. All dose regimens of agomelatine were well tolerated and no unexpected adverse event was reported. This study provides evidence of a dose effect for agomelatine between 10mg and the therapeutic dose regimen of agomelatine 25–50mg: the efficacy of the higher dose regimens being more efficacious than the lowest (10mg) daily dose. The data support a definitive statement regarding the utility of 25mg as the threshold dose for initiating agomelatine in depressed patients.